There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Joyce Ruifen Chong |
| Institution: | National University of Singapore |
| Department: | Pharmacology |
| Country: | |
| Proposed Analysis: | Research Gaps: Emerging techniques with ultra-high sensitivity such as Single molecule array (Simoa) have facilitated the rapid development of novel blood biomarkers that are in high concordance with AD pathology and neurodegeneration. While several studies have reported on the diagnostic performances of Simoa-measured blood P-tau181, Aβ42, Aβ42/Aβ40 and glial fibrillary acidic protein (GFAP) in identifying elevated brain amyloid burden, as well as NfL in detecting neurodegeneration, there is a lack of studies investigating the diagnostic performances of the derived ratios of these blood-based biomarkers. As such, the primary aim of our multi-cohorts study is to compare the diagnostic performance of Simoa-measured single biomarkers vs their derived ratios. To our best of knowledge, this is the first multi-cohorts study comparing single biomarkers vs derived ratios. Research aims: Focusing on the promising blood-based biomarkers that are closest to clinical implementation and utilizing data from multiple independent retrospective cohorts which have analysed blood biomarkers using the SIMOA platform, we aim to compare the performance of single biomarkers, namely P-tau181, Aβ42, Aβ40, NfL and GFAP, and their derived ratios, namely P-tau181/Aβ42 ratio, NfL/Aβ42 ratio, Aβ42/Aβ40 ratio and GFAP/Aβ42 ratio, in: (a) Associating with CSF/PET amyloid measurements; (b) Identifying significantly elevated brain amyloid burden (Aβ+); (c) Distinguishing between Aβ+ AD dementia and other non-AD dementias; and (d) Other suggestions from collaborators For (a) and (b): Analyses are conducted in the entire cohort (e.g. cognitively unimpaired and cognitively impaired), as well as within the cognitively unimpaired, cognitively impaired, non-demented and demented subgroups. |
| Additional Investigators | |
| Investigator's Name: | Christopher Li-Hsian Chen |
| Proposed Analysis: | Research Gaps: Emerging techniques with ultra-high sensitivity such as Single molecule array (Simoa) have facilitated the rapid development of novel blood biomarkers that are in high concordance with AD pathology and neurodegeneration. While several studies have reported on the diagnostic performances of Simoa-measured blood P-tau181, Aβ42, Aβ42/Aβ40 and glial fibrillary acidic protein (GFAP) in identifying elevated brain amyloid burden, as well as NfL in detecting neurodegeneration, there is a lack of studies investigating the diagnostic performances of the derived ratios of these blood-based biomarkers. As such, the primary aim of our multi-cohorts study is to compare the diagnostic performance of Simoa-measured single biomarkers vs their derived ratios. To our best of knowledge, this is the first multi-cohorts study comparing single biomarkers vs derived ratios. Research aims: Focusing on the promising blood-based biomarkers that are closest to clinical implementation and utilizing data from multiple independent retrospective cohorts which have analysed blood biomarkers using the SIMOA platform, we aim to compare the performance of single biomarkers, namely P-tau181, Aβ42, Aβ40, NfL and GFAP, and their derived ratios, namely P-tau181/Aβ42 ratio, NfL/Aβ42 ratio, Aβ42/Aβ40 ratio and GFAP/Aβ42 ratio, in: (a) Associating with CSF/PET amyloid measurements; (b) Identifying significantly elevated brain amyloid burden (Aβ+); (c) Distinguishing between Aβ+ AD dementia and other non-AD dementias; and (d) Other suggestions from collaborators For (a) and (b): Analyses are conducted in the entire cohort (e.g. cognitively unimpaired and cognitively impaired), as well as within the cognitively unimpaired, cognitively impaired, non-demented and demented subgroups. |
| Investigator's Name: | Mitchell Kim Peng Lai |
| Proposed Analysis: | Research Gaps: Emerging techniques with ultra-high sensitivity such as Single molecule array (Simoa) have facilitated the rapid development of novel blood biomarkers that are in high concordance with AD pathology and neurodegeneration. While several studies have reported on the diagnostic performances of Simoa-measured blood P-tau181, Aβ42, Aβ42/Aβ40 and glial fibrillary acidic protein (GFAP) in identifying elevated brain amyloid burden, as well as NfL in detecting neurodegeneration, there is a lack of studies investigating the diagnostic performances of the derived ratios of these blood-based biomarkers. As such, the primary aim of our multi-cohorts study is to compare the diagnostic performance of Simoa-measured single biomarkers vs their derived ratios. To our best of knowledge, this is the first multi-cohorts study comparing single biomarkers vs derived ratios. Research aims: Focusing on the promising blood-based biomarkers that are closest to clinical implementation and utilizing data from multiple independent retrospective cohorts which have analysed blood biomarkers using the SIMOA platform, we aim to compare the performance of single biomarkers, namely P-tau181, Aβ42, Aβ40, NfL and GFAP, and their derived ratios, namely P-tau181/Aβ42 ratio, NfL/Aβ42 ratio, Aβ42/Aβ40 ratio and GFAP/Aβ42 ratio, in: (a) Associating with CSF/PET amyloid measurements; (b) Identifying significantly elevated brain amyloid burden (Aβ+); (c) Distinguishing between Aβ+ AD dementia and other non-AD dementias; and (d) Other suggestions from collaborators For (a) and (b): Analyses are conducted in the entire cohort (e.g. cognitively unimpaired and cognitively impaired), as well as within the cognitively unimpaired, cognitively impaired, non-demented and demented subgroups. |
